Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 4Recruiting 4Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 13Lymphoid 2Other hematologic neoplasm 1Other 1Gastrointestinal 1

Conditions

Paraproteinemias 1Neoplasms 1Natural Killer/T-cell Lymphoma 1Multiple Myeloma 1Lymphoproliferative Disorders 1Immunoproliferative Disorders 1

Interventions

Rituximab 702Cyclophosphamide 645Vincristine 353Doxorubicin 309Etoposide 305Cytarabine 271Filgrastim 250Prednisone 249Methotrexate 241fludarabine phosphate 231Dexamethasone 209fludarabine 184Peripheral Blood Stem Cell Transplantation 166Radiotherapy 161Granulocyte Colony-Stimulating Factor 145Lenalidomide 144Bendamustine Hydrochloride 142Bortezomib 127Melphalan 126ibrutinib 111Busulfan 111Mycophenolic Acid 108Whole-Body Irradiation 107Tacrolimus 96Cyclosporine 87Gemcitabine 82Ifosfamide 80Calcium Dobesilate 80Alemtuzumab 80Leucovorin 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × isatuximab × Lymphoid × Clear all
NCT04763616 2026-04-27

ICING

Samsung Medical Center

Phase 2 Completed
37 enrolled
Lymphoid

Natural Killer/T-cell Lymphoma

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡